ERBB2 and neoplasm: T-DXd was prioritized over other HER2-targeted agents because its antibody-drug conjugate mechanism enables direct delivery of a topoisomerase I inhibitor to HER2-expressing tumor cells and exerts a bystander effect that enhances activity even in tumors with heterogeneous HER2 expression.